PKPaulo Klinger

Paulo Klinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paulo Klinger has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia

    by Liane Esteves Daudt, Ana Carolina Ribeiro Correa, Antonella Zanette, Antonio Vaz de Macedo, Carla Nolasco Monteiro Breviglieri, Cilmara Kuwahara, Cláudio Galvão de Castro Junior, Luciana dos Santos Domingues, Paulo Klinger, Maura Ikoma, et al.

    This article details the 2025 consensus update from the Brazilian Group for Pediatric Bone Marrow Transplantation and the Brazilian Society for Pediatric Oncology regarding hematopoietic stem cell transplantation (HSCT) for pediatric acute lymphoblastic leukemia (ALL). Allogeneic HSCT is the standard treatment for high-risk or relapsed ALL. Key indications include, in first remission, very high risk patients defined by primary induction failure or positive minimal residual disease (MRD) after consolidation. In second remission, it is indicated for early bone marrow relapse, early isolated extramedullary B-cell relapse, and all T-cell ALL relapses. The consensus recommends myeloablative conditioning as standard, preferring total body irradiation based regimens for children over 2–3 years old. The preferred donor hierarchy is a matched sibling, followed by a matched unrelated donor, with bone marrow being the preferred cell source. Post-HSCT monitoring of MRD is critical for guiding interventions and identifying relapse. This document serves as an essential, updated guide for clinical decision-making in this field.

  • Open Access

    Hematopoietic cell transplantationin pediatric chronic myeloid leukemia

    by Roseane Vasconcelos Gouveia, Mariana Bohns Michalowski, Paulo Henrique dos Santos Klinger, Luciana dos Santos Domingues, Ana Carolina Ribeiro Correa, Mariane Farherr Caleffi, Antonio Vaz De Macedo

    Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder primarily linked to the BCR-ABL fusion gene, resulting from the Philadelphia chromosome translocation. While rare in pediatric populations, CML in children presents unique biological and clinical features, often diagnosed incidentally through leukocytosis. Symptoms may include fatigue, weight loss, and splenomegaly, with advanced cases exhibiting signs of bleeding and infections. The management of pediatric CML has evolved significantly with the introduction of tyrosine kinase inhibitors (TKIs), in which imatinib remains the first-line treatment despite potential long-term toxicities. Second-generation TKIs such as dasatinib and nilotinib are alternatives for treatment resistance. Asciminib, a third-generation inhibitor, shows promise for cases resistant to other TKIs, although pediatric data are still emerging. Allogeneic hematopoietic cell transplantation (HCT) is crucial for highrisk pediatric CML cases, particularly in the blastic phase or in instances of TKI resistance. The choice of conditioning regimens, whether myeloablative or reduced-intensity, is vital, with busulfan-based regimens preferred due to lower late effects. Post-transplant, the use of TKIs can be beneficial, with molecular monitoring guiding treatment decisions. Overall, individualization of therapy considering disease phase, molecular profile, and donor availability is essential for optimizing outcomes in pediatric CML management. Close follow-up strategies involving regular molecular assessments and tailored therapeutic approaches post-HCT are critical for improving patient survival rates and managing relapses.

  • Open Access

    Hematopoietic cell transplantation in inborn errors of immunity - Part II: others

    by Juliana Folloni Fernandes, Rafaella Muratori, Gisele Loth, Ana Karine Vieira, Paulo Klinger, Simone Franco, Carmem Bonfim

    Inborn errors of immunity (IEI) are a large, heterogeneous group of disorders resulting from deficiencies in immune system development and/or function, leading to increased susceptibility to infections, autoimmunity, autoinflammation, lymphoproliferation, and malignancy. Some diseases are classical hematopoietic cell transplantation (HCT) indications, such as Wiskott-Aldrich Syndrome, but more than 150 different IEI have been transplanted. Each disease and patient should be addressed individually as the clinical manifestations are variable, as well as the pre- and post-transplant care. This consensus strongly recommends that these patients are referred to experienced centers performing HCT for IEI.

  • Open Access

    Hematopoietic cell transplantation in inborn errors of immunity Part I: severe combined immunodeficiency

    by Rafaella Muratori, Juliana Folloni Fernandes, Gisele Loth, Ana Karine Vieira, Paulo Klinger, Simone Franco, Carmem Bonfim

    Severe Combined Immunodeficiencies (SCID) are rare diseases characterized by a blockage in T-lymphocyte development. Hematopoietic Cell Transplantation (HCT) is the primary curative therapy, with the highest survival rates correlated to early diagnosis and the absence of active infections at transplant. The gold standard is a matched related sibling donor (MSD), but alternative donors like haploidentical family donors are increasingly used. Conditioning regimens vary, with reduced intensity busulfan and fludarabine often indicated. Early diagnosis via newborn screening and referral to experienced HCT centers are crucial for improving outcomes. Long-term follow-up is essential, as the cumulative incidence of late effects, such as neurologic and neurodevelopmental issues, increases over time.

  • Open Access

    Inborn errors of metabolism and osteopetrosis

    by Juliana Folloni Fernandes, Adriana Melo Rodrigues, Liane Esteves Daudt, Paulo Klinger, Carmem Bonfim

    Allogeneic hematopoietic cell transplantation (HCT) remains the standard and potentially curative therapy for certain inborn errors of metabolism (IEM) and for osteopetrosis. This paper updates the Brazilian consensus guidelines for HCT indications in pediatric patients with IEM, specifically focusing on mucopolysaccharidosis, X-linked adrenoleukodystrophy, Krabbe disease, metachromatic leukodystrophy, and osteopetrosis. We emphasize the importance of early diagnosis, timely referral, and multidisciplinary follow-up to optimize patient outcomes. Additionally, we discuss the evolving landscape of conditioning regimens and donor selection criteria, underscoring the critical need for genetic testing to guide therapy. Future directions in research, including gene therapy and novel therapeutic strategies, are also highlighted.

  • Open Access

    Hematopoietic stem cell transplantation for extracranial germ cell tumors

    by Neysimelia Costa Villela, Patricia Shimoda Ikeuti, Paulo Henrique dos Santos Klinger, Antonella Zanette, Cláudio Galvão de Castro Junior, Luiz Fernando Lopes

    Malignant extracranial germ cell tumors (GCT) are uncommon in the pediatric population. Most affected children can achieve cure using conventional chemotherapy combined with appropriate local control. The role of high-dose chemotherapy with autologous stem cell transplantation (HDCT/ASCT) in GCT has been studied mainly in adult cohorts. In this article, we reviewed the current evidence and indications for HDCT/ASCT in the management of pediatric GCT.

  • Open Access

    Hematopoietic stem cell transplantation in children with thalassemia: Brazilian Society of Bone Marrow Transplantation Consensus

    by Luiz Guilherme Darrigo Junior, Ana Karine Vieira, Cilmara Kuwahara, Roseane Vasconcelos Gouveia, Paulo Klinger, Alexandre de Albuquerque Antunes, Julia Lopes Garcia

    Allogeneic hematopoietic cell transplantation (HCT) represents a critical therapeutic option for patients with transfusiondependent thalassemia (TDT), with thalassemia-free survival rates exceeding 90% in cases involving HLA-matched sibling donors. Due to the limited availability of matched donors, alternative sources such as HLA-matched unrelated donors, haploidentical donors, and umbilical cord blood have broadened HCT eligibility. Despite its potential for cure, HCT involves risks like graft-versus-host disease, graft rejection, and transplant-related mortality. Recent improvements in conditioning regimens have enhanced patient outcomes and quality of life. Factors affecting HCT success in TDT include recipient age, disease complications, effective chelation therapy, Pesaro score, and donor compatibility. This article aimed to update the Brazilian consensus established by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, incorporating the latest advances in treating and managing TDT patients undergoing transplantation.

  • Open Access

    Central nervous system tumors

    by Gustavo Zamperlini, Paulo Henrique dos Santos Klinger, Antonella Zanette, Cilmara Kuwahara, Sidnei Epelman, Adriana Seber, Cláudio Galvão de Castro Junior

    Central nervous system (CNS) tumors represent one of the most prevalent groups of neoplasms in the pediatric population. Recent advances in molecular biology and neuro-oncology have led to continuous updates in the classification of these tumors, which poses significant diagnostic challenges, particularly in low- and middle-income countries, with limited access to advanced diagnostic tools. The therapeutic approach varies according to tumor subtype, often requiring complex and resource-intensive protocols. One such strategy involves the use of high-dose chemotherapy followed by autologous stem cell rescue, which has shown promise in improving outcomes for select pediatric patients with CNS tumors. However, implementation of this therapy in countries like Brazil faces logistical, financial, and clinical practice challenges. This article aimed to provide a brief overview and suggestions to use high-dose chemotherapy with autologous stem cell transplantation in the treatment of pediatric CNS tumors. We discussed practical considerations for patient selection, and conditioning regimens. Our objectives were to optimize and guide current practices by proposing strategies that maybe feasible in the Brazilian public and private healthcare systems.

  • Open Access

    Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia

    by Ana Luiza de Melo Rodrigues, Adriana Seber, Luciana Domingues, Victor Gottardello Zecchin, Maria Lúcia de Martino Lee, Liane Daudt, Luiza de Souza, Adriana Martins de Sousa, Antonella Adriana Zanette, Carla Nolasco, et al.

    Acute myeloid leukemia (AML) accounts for 15% to 20% of pediatric acute leukemia cases. Treatment failure is influenced by both genetic risk and response to therapy1,2,3,4. Although the initial remission rate exceeds 90%, more than 30-40% of children with AML die of refractory/relapsed disease or treatment-related toxicity5. Improved survival outcomes are associated with comprehensive strategies that combine intensive chemotherapy, effective supportive care, and hematopoietic stem cell transplantation (HCT), adjusted to the relapse risk profile of each patient6-10. In 2020, the Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) and the Brazilian Society for Pediatric Oncology (SOBOPE) convened a task force to provide general guidance on HSCT for childhood AML, to provide evidence-based guidance for the appropriate management of this disease. This is the 2025 update of the previously guideline.

  • Open Access

    Retinoblastoma

    by Paulo Henrique dos Santos Klinger, Cláudio Galvão de Castro Junior, Antonella Adriana Zanette, Neviçolino Pereira de Carvalho, Adriana Seber

    Retinoblastoma is the most common form of ocular cancer in children, with an estimated prevalence of one in every 15,000 to 20,000 births. Although it accounts for only 3% of pediatric neoplasms, its impact is significant in children under 5 years of age. It is a malignant neoplasm of the retina, of embryonic origin, with an oncogenic basis in the mutation of the tumor suppressor gene RB1 (somatic or germline). The disease can be broadly classified as intraocular or extraocular. Extraocular disease, especially in stages IVa (metastatic disease with hematogenous spread, single or multiple foci, to bone marrow, bones, liver, lymph nodes) and IVb (extension to the central nervous system, prechiasmatic lesions, or leptomeningeal disease), poses significant challenges to treatment, requiring specialized centers for referral and early diagnosis. This article reviews recent therapeutic approaches, including the use of thiotepa in high-dose chemotherapy with stem cell rescue in a single transplant, or in double schemes for patients with stage IVa and IVb at diagnosis or relapsed.